drugset / Trial / NCT03910361
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
Timeline
- Start
- 2019-04-12
- Primary completion
- 2020-07-02
- Completion
- 2020-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evogliptin | Small molecule | 5 mg | — |
| Comparator | Pioglitazone | Small molecule | 15 mg | — |